Vaccine Safety Registry
Pneumococcal Vaccine Safety
Institutional safety data for pneumococcal vaccines (PCV13, PCV15, PCV20, PPSV23). Clinical monitoring, manufacturer profiles, and adverse event surveillance.
Medically reviewed by
Dr. Simran Kohli, MBBS, MD (General Medicine), DM (Infectious Diseases)
View Clinical ProfileOpen Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Pneumococcal disease results from infection by Streptococcus pneumoniae. Pathological manifestations include community-acquired pneumonia, acute otitis media, sinusitis, bacterial meningitis, and bacteremia.
Immunization modules are categorized into conjugate (PCV) and polysaccharide (PPSV) formats. Deployment of these vaccines has significantly reduced invasive pneumococcal disease (IPD) across the pediatric-to-geriatric lifespan.
Vaccine Formulations
Module specifics & formulations
Formulation Node
Pneumococcal Conjugate (PCV)
Registry data
- PCV20 - Pfizer - 20 serogroups.
- PCV15 - Merck - 15 serogroups.
- PCV13 - Pfizer - 13 serogroups.
Formulation Node
PPSV23 (Pneumovax 23)
Merck & Co. | 23 serogroups
- Recommended for adults 65+ and high-risk triage.
Clinical Triage
Eligibility & contraindications
Pediatric Protocol
- All infants (< 2 years) for PCV series
- Children 2-4 with specific pathology
- Immunological catch-up for at-risk youth
Adult Triage
- All individuals 65 years and older
- Adults 19-64 with chronic clinical conditions
- Adult cigarette smokers
Absolute & Relative Contraindications
- Anaphylaxis to previous pneumococcal dose
- Acute moderate-to-severe illness state
- Known hypersensitivity to registry module components
Adverse Events
Reported reactions & surveillance
Local Reactions
- Localized pain
- Erythema (Redness)
- Induration (Swelling)
Systemic Profile
- Pyrexia (Fever)
- Generalized lethargy
- Loss of appetite
- Irritability (Pediatric focus)
Surveillance Analytics
Post-market surveillance metrics
1983
Registry Entry (PPSV)
40+ Years
Surveillance Data
Millions
Doses Synchronized
Institutional Surveillance
Since the introduction of conjugate modules, institutional data confirms a dramatic decrease in invasive pneumococcal disease, pneumonia hospitalizations, and meningitis mortality across all monitored cohorts.
Editorial Governance
Clinical Reviewers & Authors
Dr. Simran Kohli
MBBS, MD (General Medicine), DM (Infectious Diseases)
Infectious Diseases
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine: Updated ACIP Recommendations
MMWR Morbidity and Mortality Weekly Report, 71(4):109-117
- 2WHO2024Pneumococcal conjugate vaccines in infants and children: WHO position paper
Weekly Epidemiological Record, 94(08):85-104
- 3FDA2024PREVNAR 20, VAXNEUVANCE, and CAPVAXIVE Package Inserts & Clinical Safety Reviews
U.S. Food and Drug Administration CBER
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Nikhil Chatterjee and clinically reviewed by Dr. Simran Kohli, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.